Patent · US Active

Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors

US10487092B2 · kind B2 · utility

0Cited by

2References

22Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Anja GIESE · Berlin, DE
Ulrich Klar · Berlin, DE
Keith Graham · Berlin, DE
Georg Kettschau · Berlin, DE
Detlev Sülzle · Berlin, DE
Philip Lienau · Berlin, DE
Kirstin Petersen · Berlin, DE
Julien LEFRANC · Berlin, DE
Nicole SCHMIDT · San Francisco, US

Key dates

Filing date	Dec 14, 2015
Grant date	Nov 26, 2019
Priority date	—
Expiry date	Dec 14, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D495/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to substituted pyrazolopyridinamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, inflammatory disease and disease associated with inflammatory pain, as a sole agent or in combination with other active ingredients.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.